September 8, 2018
Written by Benjamin M. Adams
Since HIV was first identified decades ago, only five potential vaccines have been approved to test on humans. Thankfully, the summer of 2018 was brimming with news of promising advancements for contenders into human clinical trials in the race for a vaccine. Here are a few:
According to findings published in the journal Natural Medicine, one new experimental vaccine regimen is tailor-made to fit the structure of a vulnerable region of HIV. The results generated antibodies in mice, guinea pigs, and monkeys, while neutralizing dozens of HIV strains. The findings might lead to human clinical trials for a vaccine capable of neutralizing a large fraction of common HIV strains.
Led by investigators from the National Institute of Allergy and Infectious Diseases, which falls under the National Institutes of Health, a preliminary human trial of the team’s new vaccine regimen is anticipated to begin in the second half of 2019.
The study was spearheaded by Peter D. Kwong, Ph.D., chief of the Structural Biology Section at the NIAID Vaccine Research Center, and John R. Mascola, M.D., the center’s director.